Biotech Co. Pharma Co. Type/Product Area Amount Terms/Details (Date) Abgenix Inc. BASF Bioresearch (unit of BASF AG:Germany) Research collaboration; BASF will utilize Abgenix's XenoMouse technology to develop fully human antibodies to an undisclosed antigen target ND Abgenix receives up-front payment and could receive additional fees and milestones, plus royalties on future product sales (3/99) Abgenix Inc. Japan Tobacco Inc. Clinical trial support related to marketing agreement for ABX-IL8, a
State of the Industry Report | Thursday, January 3, 2002
Company Product Description Indication Action/Date Chiroscience Group plc (UK) Chirocaine Levobupivacaine; chiral version of bupavicaine Long-acting local anesthetic Received approvable letter (3/1) DUSA Pharmaceuticals Inc. (Canada) Levulan Photodynamic therapy; 20% solution of amino-levulinic acid HCl (topical) Multiple actinic keratoses of the face and scalp Received approvable letter (6/29) Ergo Science Corp. Ergoset Bromocriptine mesylate Type 2 diabetes Received approvable letter for
State of the Industry Report | Thursday, January 3, 2002
Top Ten Underwriters Full Credit To All Underwriters Underwriter (Number of IPOs as Lead/Number of IPOs As Lead Or Co-Manager) Percent Change In Stock Price Deutsche Banc Alex. Brown (1/1) 283.0 A.G. Edwards & Sons (1/1) 283.0 Goldman, Sachs & Co. (1/2) 261.0 Robertson Stephens (0/2) 261.0 Invemed Associates (0/2) 229.0 Donaldson, Lufkin & Jenrette (1/2) 207.0 Warburg Dillon Read LLC (0/3) 203.0 China Everbright Securities (0/1) 189.0 The New China Hong Kong Securities Ltd. (0/1) 189
State of the Industry Report | Thursday, January 3, 2002
Company Product Description Indication Action/Date Alza Corp. Doxil (FDAapproved) Doxorubicin HCl liposome injection Refractory ovarian cancer Oncologic Drugs Advisory Committee recommended approval of supplemental NDA (6/8) Chiroscience Group plc (UK) Chirocaine Levobupivacaine; chiral version of approved drug bupivacaine Broad usage in local, regional or spinal anesthesia FDA's Anesthetics and Life Support Drugs Advisory Committee voted unanimously to recommend approval (1/12) Ciba Vision
State of the Industry Report | Thursday, January 3, 2002
Company Company Type/Product Area Terms/Details (Month) Abgenix Inc. AVI BioPharma Inc. License and option agreement; use of Abgenix?s XenoMouse technology to develop fully human antibodies to human chorionic gonadotropin (hCG) for treating cancer AVI licensed technology to generate product candidates; AVI responsible for product development, manufacturing and commercialization; Abgenix gets certain payments, milestones and royalties (1/99) Abgenix Inc. Genentech Inc. New, multi-product
State of the Industry Report | Thursday, January 3, 2002
Company Product Description Indication Action/Date Biota Holdings Ltd. (Australia) and Glaxo Wellcome plc Relenza Zanamivir; neuraminidase inhibitor (designed and synthesized based on crystal structure of surface proteins of influenza virus); inhaled in powder form Treatment and prevention of influenza A and B FDA's antiviral drugs advisory committee voted against recommending approval (2/24) Gilead Sciences - Adefovir dipivoxil 60 mg; reverse transcriptase inhibitor HIV infection Presented
State of the Industry Report | Thursday, January 3, 2002
Company Product Description Indication Action/Date Agouron Pharmaceuticals Inc. (a subsidiary of the WarnerLambert Co.) Viracept (FDAapproved) Nelfinavir mesylate; synthetic small-molecule HIV protease inhibitor HIV infection FDA approved twice-daily dosing based on Phase III trial results (12/1) Alkermes Inc. and Genentech Inc. Nutropin Depot Sustained-release formulation of Genentech's recombinant growth hormone based on Alkermes' ProLease injectable delivery system (administered once or
State of the Industry Report | Thursday, January 3, 2002
Biotech Company Agribusiness Partner Type/Product Area Amt. Terms/Details (Month) 3-Dimensional Pharmaceuticals Inc. Hoechst Schering AgrEvo GmbH (Germany) Research collaboraation/use of 3D's compound libraries and DirectedDiversity optimization technology to discover and refine new agrochemicals ND AgrEvo has exclusive rights to commercialize agricultural products discovered during the collaboration; 3D retains rights for non-agrochemical uses of compounds developed through the collaboration
State of the Industry Report | Thursday, January 3, 2002
Company Location Amount (M) Investors (Month) 3-Dimensional Pharmaceuticals Inc. (4th round) Exton, Pa. 10.4 The company raised $10.4M from BB Biotech in this self-managed financing (1/98) Acadia Pharmaceuticals (other) San Diego 1.4 The company received $1.4M from the exercise of certain warrants held by the group of institutional investors that participated in its 1st financing round (2/97); these included BankInvest, Dansk Kapitalanlaeg A/S, LD Pension Fund and Municipal
State of the Industry Report | Thursday, January 3, 2002
Company** University/Non-Profit[Scientist] Type Of Agreement Product Area Details (Month) Advanced Magnetics Inc. The University of Minnesota [Carston Wagner] Research collaboration Development of nucleoside therapeutics with anti-viral or antitumor characteristics Advanced Magnetics will sponsor research over 3 years (7/98) Advanced Tissue Sciences Inc. The Massachusetts Institute of Technology and Children?s Hospital, Boston License Technology for growth of
State of the Industry Report | Thursday, January 3, 2002
By Mary Welch In terms of mergers and acquisitions, 1998 may very well be the year the proverbial dam broke. ?It may be the year we saw the first trickle opening of the flood gates in terms of activity,? said Paul Boni, a vice president at Punk, Ziegel & Co., in New York. David Steinberg, an analyst with Volpe, Brown, Whelan & Co., in San Francisco, concurred that last year was ?as active a year as there was in the entire decade. There were a number of acquisitions. Elan Corp. for instance
State of the Industry Report | Thursday, January 3, 2002
Senior Staff Writer The biotechnology industry and those investing in it are maturing. That s not necessarily good news for the many companies still in their adolescence. No longer will start-up companies and those still in their formative years be able to raise capital as easily as they did in the early years of the industry, based solely on promising preclinical science or early clinical results. Analysts following the industry speak of a bifurcation of companies in the sector, a separation of
By Jim Shrine | State of the Industry Report | Thursday, January 3, 2002
Washington Editor In Washington, l affaire Lewinsky not only left the executive branch dealing with and surrounded by an historic level of distraction, but also provided fodder for the partisan rancor that has pervaded since the opening of the 104th Congress in 1995. I did not like to see this new, all-time high level of partisanship on the Hill this year, said Carl Feldbaum, president of the Biotechnology Industry Organization (BIO). It really resulted in a virtual inability to form consensus
By Lisa Seachrist | State of the Industry Report | Thursday, January 3, 2002
Company (Symbol) Offer Date Number Shares/ Units (M)* Price Per Share/ Unit ($) Gross ($M)* Net ($M) Shares Out (M) Fully Diluted (M) Post- Offering Market Cap ($M) Lead Under- Writer Other Under- Writers CV Therapeutics Inc. (CVTX) 1/22 2.58S 8.25 21.2 19.7 11 13.9 91 JPM UBS, IA Pharmacyclics Inc. (PCYC) 1/30 2.01S 21.75 43.8 40.9 12.2 13.6 264 HQ CC, PGE GelTex Pharmaceuticals Inc. (GELX) 3/19 3.0S 27 81 62.3 16.1
State of the Industry Report | Thursday, January 3, 2002
Collaborations, Agreements, Equity Participation Company** Company# Type/Product Area Terms/Details (Date) Abgenix Inc. Genentech Inc. Research collaboration; use of Abgenix?s XenoMouse technology to generate fully human monoclonal antibodies to undisclosed Genentech antigen in area of growth factor modulation Genentech gets right to use Xeno- Mouse technology and has option on license; if it exercises option, Abgenix gets license fees, milestones and royalties; Genentech
State of the Industry Report | Thursday, January 3, 2002
I. Top Ten Underwriters: Initial Public Offerings Full Credit to Lead Underwriter Underwriter (Number of IPOs as Lead Underwriter) Percent Change In Stock Price (Post-IPO to Year-End) Goldman, Sachs & Co. (1) 344.0 Donaldson Lufkin & Jenrette (1) 300.0 Deutsche Bank BT Alex. Brown (1) 283.0 Westport Resources Investment Services (1) 189.0 Canaccord Capital Corp. (1) 181.0 Lehman Brothers (1) 131.0 Credit Suisse First Boston Corp. (1) 114.0 J.P. Morgan & Co. (2) 108.0 ING Barings LLC
State of the Industry Report | Thursday, January 3, 2002
Biotech Company** Pharma Company(Symbol) Type/Product Area Amount Terms/Details(Month) Abgenix Inc. Schering-Plough Research Institute (unit of Schering-Plough Corp.; NYSE:SGP) Collaborative research agreement; use of Abgenix?s XenoMouse technology to generate fully human monoclonal antibodies to an undisclosed target antigen of Schering-Plough?s ND Schering-Plough has option to enter research and license agreement under which Abgenix would get additional research and milestone
State of the Industry Report | Thursday, January 3, 2002
I. Modified Agreements Biotech Company** Pharma Company(Symbol) Type/Product Area Amount Terms/Details (Month) Abgenix Inc. Pfizer Inc. (NYSE:PFE) Expansion of 12/97 collaboration and license agreement on use of Abgenix?s XenoMouse technology to make fully human antibodies to 3 of Pfizer?s antigen targets $10M Pfizer exercised option for 2nd antigen target (undisclosed; 1st target is for oncology applications); with exercise of option, Abgenix gets $10M in cash plus royalties (10
State of the Industry Report | Thursday, January 3, 2002
I. Completed Mergers And Acquisitions Company Acquired Acquired By Or Merged With Date Announced Date Completed Value (M) Terms/Details Microbiology business of AccuMed International AMI Acquisition Corp.* 12/98 1/99 15.25 For the sale of AccuMed?s microbiology business; AMI is a joint venture between Key Equity Capital and Michael Burke, a former AccuMed executive ACT Gene SA* (France) Visible Genetics Inc. (Canada) - 4/98 1.3 Visible Genetics acquired ACT Gene for
State of the Industry Report | Thursday, January 3, 2002
Biotech Co. Pharma Co. Type/Product Area Amount Terms/Details (Date) Abgenix Inc. BASF Bioresearch (unit of BASF AG:Germany) Research collaboration; BASF will utilize Abgenix's XenoMouse technology to develop fully human antibodies to an undisclosed antigen target ND Abgenix receives up-front payment and could receive additional fees and milestones, plus royalties on future product sales (3/99) Abgenix Inc. Japan Tobacco Inc. Clinical trial support related to marketing agreement for ABX-IL8, a